Fusion proteins for specific treatment of cancer and autoimmune diseases
OwnerMathieu Hubertus, M. Noteborn, Johan Renes +1inventors
InventorsMathieu Hubertus, M. Noteborn, Johan Renes, Ying-Hui Zhang
Life of this patent
Estimating the term…
Abstract
The invention relates to the field of apoptosis. The invention provides novel therapeutic substances, for example novel therapeutic (non-)viral vectors or proteinaceous compounds, that contain apoptin in conjunction with cytotoxic agents, especially in those cases when cells are derailed, such as in cancer- and autoimmune-derived cells.
Claims15
A fusion protein comprising a polypeptide providing cytotoxicity, said polypeptide being fused to a moiety rendering the fusion protein functionally available in aberrant cells and not functionally available in non-aberrant cells.
A method of inducing cell death in aberrant cells, said method comprising:
- administering a fusion protein having a moiety rendering the fusion protein functionally available in aberrant cells and not functionally available in non-aberrant cells.
A gene delivery vehicle encoding a fusion protein comprising a moiety rendering the fusion protein functionally available in aberrant cells and not functionally available in non-aberrant cells.
A method for providing aberrant cells predominantly over normal cells with a desired fusion protein comprising administering a fusion protein having a moiety rendering the fusion protein functionally available in aberrant cells and not functionally available in nonaberrant cells.
Dependencies are inferred from the claim text.